ID   Parks
AC   CVCL_DN32
SY   PARKS
DR   Wikidata; Q54937580
RX   PubMed=21908323;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=31175136;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Partially contaminated. Some stocks of this cell line seemed to have been contaminated by a unknown human cell line (PubMed=21908323).
CC   Part of: FACC canine tumor cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00444.
CC   Doubling time: 30 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; 39068; CDKN1A; Simple; p.Asp33fs (c.97delG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 54830; EIF1AX; Simple; p.Gly6Ser (c.16G>A); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 43120; MED12; Simple; p.Pro22Ser (c.64C>T); Zygosity=Homozygous (PubMed=31175136).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 231,239
ST   Dog FHC2054: 156
ST   Dog FHC2079: 275,279
ST   Dog PEZ1: 115
ST   Dog PEZ3: 119
ST   Dog PEZ5: 111
ST   Dog PEZ6: 183
ST   Dog PEZ8: 240
ST   Dog PEZ12: 270
ST   Dog PEZ20: 176
DI   NCIt; C120298; Canine melanoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 21-03-23; Version: 11
//
RX   PubMed=21908323; DOI=10.1177/1040638711408064;
RA   O'Donoghue L.E., Rivest J.P., Duval D.L.;
RT   "Polymerase chain reaction-based species verification and
RT   microsatellite analysis for canine cell line validation.";
RL   J. Vet. Diagn. Invest. 23:780-785(2011).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//